INTS
NASDAQ · Biotechnology
Intensity Therapeutics Inc
$5.93
+0.05 (+0.85%)
Financial Highlights (FY 2025)
Revenue
3.04M
Net Income
-338,512
Gross Margin
49.9%
Profit Margin
-11.1%
Rev Growth
+8.4%
D/E Ratio
0.32
Revenue & Net Income
Margin Trends
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Gross Margin | 49.9% | 49.9% | 49.9% |
| Operating Margin | -12.1% | -11.2% | -11.7% |
| Profit Margin | -11.1% | -10.7% | -13.8% |
Income Statement
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 3.04M | 2.78M | 2.85M |
| Gross Profit | 1.52M | 1.38M | 1.42M |
| Operating Income | -368,817 | -312,128 | -334,525 |
| Net Income | -338,512 | -296,423 | -392,127 |
| Gross Margin | 49.9% | 49.9% | 49.9% |
| Operating Margin | -12.1% | -11.2% | -11.7% |
| Profit Margin | -11.1% | -10.7% | -13.8% |
| Rev Growth | +8.4% | -9.6% | +19.4% |
Balance Sheet
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Total Debt | 2.02M | 2.04M | 2.26M |
| Total Equity | 6.25M | 6.09M | 6.50M |
| D/E Ratio | 0.32 | 0.33 | 0.35 |
Cash Flow
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| EBITDA | -526,054 | -452,617 | -411,641 |
| Free Cash Flow | -211,518 | -295,521 | -239,156 |